. siRNA sequences used in this study 16 The synthesis and characterization of the compounds are further detailed below. The synthesis and characterization of the compounds are further detailed below. Upon storage in PBS at +4°C, CSL3-based LNP are stable for >7 days. When incubated in buffer containing 10% FBS, LNP remain stable for 10h at 37°C. Nevertheless, aggregation occurs at the 10-hour and 1-hour time point in 10% and 50% FBS respectively. This partial serum instability could result in the premature release of siRNA in the blood stream following intravenous injection, explaining the relatively high fluorescent signal observed in the kidneys in the biodistribution study (see Figure S10 ). Statistical analyses were performed using Prism ® 6 (GraphPad Software, La Jolla, CA, USA).
Synthesis of the pH-sensitive cationic switchable lipids CSL1 and CSL3
Synthesis of compounds 1 & 2
In a 250 mL round-bottom flask previously purged with argon was added sodium hydride (60% dispersion in mineral oil, un-rinsed) (926 mg / 27.6 mmol). Anhydrous THF (130 mL) was added, and 2,6-dibromopyridin-4-amine 4 (1736 mg / 6.89 mmol) was slowly dissolved in the mixture. 2-iodo-N,N-dimethylethan-1-amine (iodide salt) 5 (2253 mg / 6.89 mmol) was added and the mixture was stirred 0.5 hours at 80°C under argon. The mixture was then slowly quenched with MeOH, and dry loaded into column chromatography on silica gel for purification (hexane/AcOEt, fast gradient from 100:0 to 0:100 ; DCM/MeOH, gradient from 100:0 to 70:30) using a Teledyne Isco CombiFlash ® purification system. The final product 1 was obtained as a yellow solid (1386 mg / 62%) and the final product 2 was obtained as a slightly orange solid (395 mg / 15%). 
Synthesis of compound 3
In a 250 mL round-bottom flask previously purged with argon was added sodium hydride (60% dispersion in mineral oil, un-rinsed) (654 mg / 19.5 mmol). Anhydrous THF (50 mL) was added, and 1 (786 mg / 2.43 mmol) was added to the mixture. Methyl iodide was added (449 mg / 3.16 mmol). The reaction was stirred at 40°C 
Synthesis of compound 4
In a 50 mL round-bottom flask was dissolved 2 (127 mg / 0.32 mmol) and 5-bromo-2-methoxyphenylboronic acid (170 mg / 0.74 mmol) in 4 mL of THF. Na 2 CO 3 (137 mg / 1.29 mmol), previously dissolved in 4 mL of distilled water, was added and the flask was purged three times with argon. Pd(PPh 3 ) 4 (3.7 mg / 0.003 mmol)
was added and the flask was purged three times again. The mixture was stirred 48 hours at 80°C. The reaction was monitored by LC-MS until entire consumption of the starting materials. The mixture was then diluted with saturated Na 2 CO 3 and extracted 3 times with dichloromethane (DCM). The organic layer was dried over MgSO 4 and evaporated under vacuum. The crude product was purified by reverse phase preparative HPLC on an Agilent Zorbax PrepHT Eclipse XDB-C18 21.2x150mm (5µm) column. Mobile phase A was composed of water + 0.1% formic acid and mobile phase B was composed of MeOH + 0.1% formic acid. The mobile phase gradient was: 0 min -15 % B ; 6 min -80 % B ; 12 min -80 % B followed by a column re-equilibration time of 4 min. 
Synthesis of compound 5
In a 100 mL round-bottom flask was dissolved 3 (694 mg / 2.06 mmol) and 5-bromo-2-methoxyphenylboronic acid (1189 mg / 5.15 mmol) in 6 mL of THF. Na 2 CO 3 (873 mg / 8.24 mmol), previously dissolved in 6 mL of distilled water, was added and the flask was purged three times with argon. Pd(PPh 3 ) 4 (23.8 mg / 0.021 mmol) was added and the flask was purged three times again. The mixture was stirred 48 hours at 80°C. The reaction was monitored by LC-MS until entire consumption of the starting materials. The mixture was then diluted with saturated Na 2 CO 3 and extracted 3 times with dichloromethane (DCM). The organic layer was dried over MgSO 4 and evaporated under vacuum. The final product was purified using a Teledyne Isco CombiFlash ® purification system equipped with a 30 grams reversed-phase C18 HP Gold column. Mobile phase A was composed of water + 0.1% formic acid and mobile phase B was composed of MeOH + 0.1% formic acid. The mobile phase gradient was: 0 min -20 % B ; 15 min -90 % B followed by a column re-equilibration time of 4-5 CV.
Compound 5 was obtained as a white solid (492 mg / 47% 
Synthesis of compound 7
To a solution of 6 (1.5 g / 5.08 mmol) in DCM (25 mL) was slowly added Boc 2 O (1.33 g / 6.10 mmol). The medium was stirred at room temperature during 2h and then washed with saturated Na 2 CO 3 . The organic layer was decanted and the aqueous layer was extracted twice with DCM. The combined organic layers were dried over MgSO 4 and concentrated under reduced pressure to afford a brown oil. The crude was purified by chromatography on silica gel (hexane/AcOEt, gradient from 100:0 to 0:100) using a Teledyne Isco CombiFlash ® purification system to afford 7 (1.6 g / 79%) as an orange oil. 1 
Synthesis of compound 9
In a 50 mL round-bottom flask was dissolved 8 (240 mg / 0.59 mmol) and 5-bromo-2-methoxyphenylboronic acid (340 mg / 1.47 mmol) in 5 mL of THF. Na 2 CO 3 (249 mg / 2.35 mmol), previously dissolved in 5 mL of distilled water, was added and the flask was purged three times with argon. Pd(PPh 3 ) 4 (8.2 mg / 0.012 mmol) was added and the flask was purged three times again. The mixture was stirred 48 hours at 80°C. The reaction was monitored by LC-MS until entire consumption of the starting materials. The mixture was then diluted with saturated Na 2 CO 3 and extracted 3 times with dichloromethane (DCM). The organic layer was dried over MgSO 4 and evaporated under vacuum. The crude was dry loaded into column chromatography on silica gel for purification (hexane/AcOEt, gradient from 100:0 to 0:100) using a Teledyne Isco CombiFlash ® purification system to afford 9 (179 mg / 49%) as an orange solid. 1 
Synthesis of compound CSL2
Compound 10 (141 mg / 0.179 mmol) was dissolved in EtOH in a 100 mL round-bottom flask. Palladium (10 wt %Pd basis) on activated charcoal (50 mg) was added and the flask was purged 3 times with hydrogen. The mixture was then stirred 4 hours at room temperature under a 1 atm hydrogen pressure. The solution was then filtered on a PTFE filter (0.20 µm) to remove the catalyst, and the organic phase was evaporated under vacuum. The oily crude was dissolved in 4M HCl in dioxane (2 mL) and was stirred 2 hours at room temperature. The mixture was then slowly diluted with saturated Na 2 CO 3 and extracted 3 times with DCM. The organic layer was dried over MgSO 4 and evaporated under vacuum. The final product was purified by reverse phase preparative HPLC on an Agilent Zorbax PrepHT Eclipse XDB-C8 21.2x100mm (5µm) column. Mobile phase A was composed of water + 0.1% formic acid and mobile phase B was composed of MeOH + 0.1% formic acid.
The mobile phase gradient was: 0 min -30 % B ; 10 min -95 % B ; 12 min -95 % B followed by a column re- 
Synthesis of the negative control cationic lipid CSL4

Synthesis of compound 11
In a 50 mL round-bottom flask was dissolved 3 (171 mg / 0.51 mmol) and 3-bromophenylboronic acid (234 mg / 
Lipid nanoparticle preparation by manual extrusion
Lipid nanoparticles for in vitro studies were prepared by manual extrusion, using cationic switchable lipids 
In vitro siRNA transfection assays
The RNAi induced silencing capabilities of each cationic switchable lipid was investigated in a HeLa/GFP model. 
In vitro cytotoxicity assay
Cytotoxicity of the lipid nanoparticles (made by manual extrusion) on HeLa/GFP cells was assessed using a resazurin-based cell viability assay (AlamarBlue ® ). The transfection procedure was strictly identical to that 
Lipid-mixing assay
The fusogenic potential of the CSL3/siRNA and CSL4/siRNA lipid nanoparticles was evaluated with an octadecyl Rhodamine B (R18) lipid-mixing assay. 1, 8 R18 was incorporated into the lipid nanoparticles at a self-quenched concentration of 6 mol%. Unlabeled 130 nm POPC vesicles were prepared in 5% dextrose using the manual extrusion method previously described (9 passages through a 200 nm polycarbonate membrane). R18 labeled lipid nanoparticles (CSL/DSPC/cholesterol/DSPE-PEG 2000 /R18 50:10:31.5:2.5:6 mol% -made by manual extrusion) were complexed with anti-GFP siRNA as described above (N/P ratio of 4, in 5% dextrose). These labeled lipid nanoparticles were mixed with unlabeled POPC vesicles in a buffer at pH 7.4 (5 mM HEPES with ionic strength adjusted to 150 mM with NaCl) or at pH 5 (50 mM acetic buffer with ionic strength adjusted to 150 mM with NaCl), as described below.
In 3000 µL of buffer containing unlabeled POPC vesicles (100 µM total lipid content in the cuvette) were added the labeled lipid nanoparticles/siRNA (50 µL volume; 10 µM total lipid content in the cuvette). where I o is the initial fluorescence intensity observed immediately after addition of labeled lipid nanoparticles;
I 100% is the maximal fluorescence intensity value obtained after addition of detergent and I t is the fluorescence intensity value measured at a given time t. Experiments were realized in triplicate.
Inhibition of GFP knockdown with Bafilomycin A1
In Discrimination of the clathrin and caveolae uptake pathways was not intended, because of the rather questionable specificity of the pharmacological endocytosis inhibitors between these two pathways. 12, 14, 15 Residual DMSO in the assay was 0.2% v/v (treated cells and negative control).
Uptake inhibition by flow cytometry
HeLa cells were seeded in 12-well plates (100 000 cells/well) and allowed to attach overnight. The next day, 
Lipid nanoparticle preparation by microfluidic mixing
Lipid nanoparticles were prepared according to previously reported procedures 16, 17 , using a Nanoassemblr TM microfluidic instrument with herringbone rapid mixing features (Precision Nanosystems, Vancouver, BC, Canada). Cationic switchable lipids, DSPC, cholesterol and DMG-PEG 2000 were solubilized in ethanol at a molar ratio of 50:10:37.5:2.5. siRNA was diluted in 25 mM sodium acetate buffer pH 4.0. The siRNA/total lipid mass ratio was ~0.06, corresponding to a N/P ratio of 4. The two solutions were mixed at a flow rate of 12 mL/min, at a siRNA solution/lipid solution ratio of 3:1. Total volume of a batch is typically 2 mL (1.5 mL siRNA solution mixed with 0.5 mL of lipid solution). Nanoparticles were then dialyzed against saline (NaCl 0.9%) using Pur-ALyzer TM Maxi dialysis tubes MWCO 12-14 kDa (Sigma). If needed, nanoparticles were concentrated using Amicon Ultra-0.5 30K centrifugal filters device (EMD Millipore, Etobicoke, ON, Canada). Nanoparticles were then sterile filtered using a 0.2µm polyethersulfone 13 mm syringe filter (Pall Corporation, Mississauga, ON, Canada) and stored at 4°C until use. The siRNA encapsulation efficiency was quantified using a Ribogreen RNA quantitation assay (Thermo Scientific). 18 Nanoparticle size was measured by Dynamic Light Scattering in saline (0.9% NaCl) at 20°C as previously described.
The final siRNA concentration was determined via ion-pairing reversed phase liquid chromatography, according to a previously reported procedure. 19 siRNA were analyzed using a Waters XTerra ® MS C 18 column (2.1x50mm, 2.5 µm particle size) at 60°C on an Agilent 1100 HPLC system, with UV detection at 260 nm. Mobile phase A was 95% 0.1M triethylamine ammonium acetate (TEAA) pH 7.0 and 5% acetonitrile. 
